Alzheimer's disease (AD) is a challenging, progressive neurocognitive disorder with no current cure. A promising approach emerging from recent studies focuses on maintaining intracellular levels of nicotinamide adenine dinucleotide (NAD+), a crucial molecule for cellular health and longevity. Boosting NAD+ levels, particularly through its precursors, nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), has shown potential as a therapeutic strategy for AD.

A recent systematic review looked at studies from the last five years to explore the therapeutic value of NAD+ precursors in treating AD. The review followed PRISMA guidelines, analyzing research from multiple databases. Three studies on NMN showed promising results in preclinical mouse models of AD, though human trials for NMN in AD remain absent. In contrast, NR has seen more clinical attention. Four preclinical studies highlighted its benefits in treating AD, and two clinical trials showed significant improvements in AD biomarkers and cognitive performance following NR supplementation in humans.

The evidence from both preclinical and early clinical studies suggests that NAD+ precursors could play a valuable role in addressing Alzheimer’s disease. However, additional clinical research is needed to confirm these findings and potentially establish NAD+ precursors as a reliable, effective intervention for AD in medical practice. As research progresses, NAD+ boosting compounds may become an important tool in AD management, holding promise for improved quality of life for those affected.